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Abstract
Background: Seasonal influenza contributes substantially to the burden of communicable diseases in Europe,
especially among paediatric populations and the elderly. The aim of the present study was to estimate the
incidence of seasonal influenza in Germany, the probabilities of related complications and the economic
burden of influenza per case and on a population level for different age groups.
Methods: Claims data from 2012 to 2014 from > 8 million insured of a large German sick-ness fund were
analysed. A matched case control study was used on a sub-sample of 100,000 influenza cases to calculate
complication rates for ear infections/acute otitis media (AOM) and community-acquired pneumonia (CAP) as
well as resource use and costs for seven age groups.
Results: Incidence of seasonal influenza varies between the years and is highest among infants and children
2 to 5 years of age. AOM is more likely in the younger age groups with up to 14% more patients in the
influenza group than in the control group. CAP is more frequently observed in the younger age groups and
in influenza patients 60 years and older. The manifestation of one influenza complication (AOM or CAP)
significantly in-creases the occurrence of a second complication (AOM or CAP). The economic burden per
case is highest in infants (€251.91) and persons over 60 years of age (€131.59).
Conclusion: The burden of influenza is highest among infants and young children, which is also reflected in
the economic burden. Influenza related costs per case are nearly double for infants compared to persons
over 60 years of age.
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Background
Seasonal influenza is an acute viral respiratory infection
that poses a substantial burden on individuals, popula-
tions, and health care systems every year. It can cause
mild to severe illness and can present with symptoms
such as fever, muscle aches, fatigue, headache, and
respiratory symptoms. While most people recover from
influenza illness within a few days [1], some may develop
severe complications including primary influenza virus
pneumonia or secondary bacterial pneumonia [2].
Infected children often suffer from AOM [3, 4]. Severe
non-pulmonary complications include cardiovascular
and neurologic complications, which are, however,
widely under-recognized since they are often not clearly
linked to a previous influenza infection [5]. People at
high risk for complications include very young children,
older adults, pregnant women, nursing home residents,
and people with chronic medical conditions or a com-
promised immune system [6].
Several vaccines are available to prevent influenza
virus infections, and in many industrialized countries,
high risk groups are targeted by national immunization
programs or immunization recommendations [7]. In
Germany, influenza vaccination is recommended for all
persons above 60 years of age, pregnant women, high-
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risk persons (e.g. diabetes patients) and health care pro-
fessionals [8]. The recommendation did not specify
whether a tri- or tetra-valent vaccine should be used
until 2018. Since then, a tetra-valent vaccine is recom-
mended. The protection through the vaccination is also
dependent on the vaccination rates. A decrease of the
vaccination rates can be observed for Germany [9]: In
the 2008/09 season 47.9% of persons above 60 years of
age were vaccinated while only 34.8% were vaccinated in
the 2016/17 season.
In this context, estimating the influenza-related
disease burden in terms of morbidity, mortality, and eco-
nomic consequences is an important contribution to the
decision-making process regarding policies around influ-
enza immunization [10]. In many countries, data on
disease burden caused by seasonal influenza viruses are
mainly gathered through national surveillance systems.
Such systems often have a strong focus on assessing the
role of influenza in acute respiratory illnesses (ARI) or
influenza-like-illnesses (ILI) or report the proportion of
cases with laboratory-confirmed influenza (LCI). In
addition, using the example of the United States, com-
bining routinely collected surveillance data with results
of outbreak investigations and health care surveys allows
for estimating symptomatic community illnesses,
outpatient medical visits, hospitalizations, and excess
deaths related to seasonal influenza [11]. The estimation
of some of these outcomes, particularly influenza-associ-
ated hospitalization rates and excess deaths, commonly
involves the use of statistical models [12]. The focus of
the German surveillance system also includes estimated
excess rates for influenza-associated outpatient medical
visits, hospitalizations, cases of absenteeism, and deaths
[13]. However, these reports do not include estimates
for complications such as AOM or CAP and provide
therefore rather partial insights in the burden of seasonal
influenza. Furthermore, the German surveillance reports
provide no information on the related direct and indirect
cost of influenza. To close this evidence gap the aim of
this study is to estimate the epidemiology of influenza
and associated costs using claims data of a German sick-
ness fund.
Methods
Data
Claims data from a large German statutory sickness fund
(2012: 8,038,608 insured, 2013: 8,412,199, 2014: 8,849,
736) covering a 3-year period (January 2012 to Decem-
ber 2014) was used to conduct the analysis. During this
period, influenza strains were evenly distributed among
the samples taken for the virological surveillance of the
National Reference Center for Influenza for the 2012/13
season (A (H3N2): 31%; A (H1N1): 34; B-lineage: 35%).
In the two following seasons, A (H3N2) was responsible
for most cases (61 and 62%, respectively) with A (H1N1)
being found in 30 and 15% and the two strains from the
B-lineage in 9 and 23% of the cases. Yamagata has been
the dominant B-strain in all seasons and has also been
included in the trivalent vaccine [14]. The claims data
set covers a broad range of medical and economic infor-
mation from insured such as diagnoses, resource use
and cost data, but primarily serves sickness funds for ac-
counting purposes. Statutory sickness funds are covering
90% of the German population and cover the expend-
iture for health services from inpatient and outpatient
sector as well as pharmaceuticals, remedies and aids and
other services.
Due to the nature of the dataset, no laboratory-con-
firmed definition of influenza cases could be used. In-
stead, an influenza or ILI case was defined via ICD-10
codes J09 to J11 which were either documented in the
dataset as a main inpatient diagnosis or a “secured” or
“suspected” outpatient diagnosis. Influenza incidence
estimates were based on all insured, while complication
rates, costs, and work days lost were analysed via a
matched case-control design. A sample of 100,000
persons being representative by age group, sex and in-
surance status for all insured diagnosed with influenza
were drawn from the total population of insured, and
controls without influenza diagnosis were matched one-
to-one with replacement by 27 age groups, sex, category
of insured persons (e.g. unemployed, employed, student),
and outpatient pharmaceutical costs of the previous year
with a caliper of ±10% as a proxy for comorbidity. Po-
tential complications of influenza were identified using
the ICD codes H65, H66, and H67 for ear infections or
AOM and J10.0, J11.0, and J12 to J18 for CAP.
Analysis
The calculation of the incidence was based on all
insured of the sickness fund. All other analyses were
based on the data of those insured for which a match
could be identified. As outpatient diagnosis informa-
tion in German claims data are usually documented
on a quarterly base, the exact day of the influenza
diagnosis cannot be determined. Therefore, the quar-
ter of the initial influenza diagnosis (index quarter)
and the following quarter were used to compare the
documented diagnoses, resource use, and costs of the
influenza patients and their matched controls. This
means that the resource use and costs are calculated
for half a year. To minimize the influence of outliers
and to ensure meaningful results for rare events (e.g.
influenza-related hospitalizations), the initial 27 age
groups that were used for matching purposes were
merged into six groups (“0 to 1”, “2 to 5”, “6 to 9”,
“10 to 17”, “18 to 34”, “35 to 59”, “60 plus”) for the
actual analysis. The choice of the age groups was
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based on to the different levels of the German educa-
tional system.
For the calculation of complication rates, the number
of persons with at least one diagnosis of AOM or CAP
during the index quarter and the following quarter was
counted. Age and year-specific complications rates were
calculated for both the influenza group and the control
group. Influenza-attributable complication rates were
then derived from the difference between the groups.
The calculation of influenza-attributable resource use
and costs differed by health care sector. For inpatient
treatment and sick leave, the corresponding principal
diagnosis was identified directly from the claims data,
i.e. ICD codes were available for each item of resource
use on a daily base. Hence, there was no need of using
the control group data for inpatient costs and sick leave.
Inpatient costs could directly be determined by the
payments of the sickness fund to the hospitals. For the
indirect costs due to sick leave, the number of days ab-
sent from work was retrieved from the claims data. As
income was not included in the dataset, the age-specific,
average daily income of an employee (including part-
time employees) [15] was used and multiplied with the
number of days of the sick leave. Indirect costs were not
calculated for the three youngest age groups and only
for employed persons in the other age groups.
For outpatient physician consultations and prescribed
pharmaceuticals, a direct link between diagnosis infor-
mation and resource use or cost data was not possible.
Therefore, respective influenza-attributable resource use
had to be calculated via the matched case-control
approach, i.e. excess resource use and costs were
estimated by calculating the difference between the
influenza group and the control group for the index
quarter and the following quarter. The analyses of phar-
maceuticals were further restricted to a list of relevant
ATC codes for the treatment of influenza and related
complications, which was adopted from Ehlken et al. [16].
The relevant ATC-codes are listed in Table 1.
The analyses were stratified by age groups to reflect
the different risk-groups and by year to account for vary-
ing influenza activity in different seasons. Detailed
results for years and age groups can also be found in a
table in the Additional file 1.
Statistics
Cost data from 2012 and 2013 were adjusted to the price
level of the reference year 2014. The health-specific con-
sumer price index of the German federal statistical office
was used to adjust prices between 2012 and 2013 (−
3.7%) and between 2013 and 2014 (2.0%). Differences
between the influenza group and the control group were
tested using the two-sample, two-sided t-test for samples
with unequal variances. Tests across k > 2 groups (e.g.
comparison across years) were corrected for multiple
testing by adjusting the alpha level by alpha/k according
to the Bonferroni correction [17]. Analyses were
performed with R (Version 3.4.1) and Microsoft Excel
(Version 2013). We followed the German guidelines on
routine data analysis [18].
Results
Study population
Across all 3 years, a match was found for 95,089 of the
100,000 insured sampled with influenza. The compari-
son of the sample characteristics between the matched
and unmatched population can be found in Table 2.
There is a significant difference between the two groups:
Persons for which no matching partner could be found,
are significantly younger (one-sided t-test), have a
slightly different sex distribution, a different distribution
of the category of insured persons, and show an unequal
distribution over the years (chi-squared tests). The final
dataset contained 190,178 persons with 95,089 influenza
cases and 95,089 controls.
Epidemiology
Influenza incidence
The overall influenza incidence was 9.26, 17.90, and 8.00
cases per 1000 insured persons for the years 2012, 2013,
and 2014, respectively. Across all 3 years, incidence was
highest in children aged < 6 years and lowest in persons
aged 60 years and above (see Fig. 1). The highest inci-
dence was found for children aged 2 to 5 years in the
Table 1 ATC-codes related to the treatment of influenza and included in the analyses
Substance Code
Analgesics and antipyretics N02B
Anti-inflammatory and anti-rheumatic products, non-steroids M01A
Nasal decongestants R01AA, R01AB
Throat preparations R02A
Cough and cold preparations R05
Antibiotics J01A, J01C, J01D, J01F, J01 M
Antivirals J05AH
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Table 2 Characteristics of the study population, stratified by successful matching
Variable Level Total
sample
Cases (N =
95,089)
Controls (N =
95,089)
No matching partner
found (N = 4911)
p-value for difference matched
vs. unmatched
Year 2012 (%) 25,223
(25.2%)
23,702
(24.9%)
23,702 (24.9%) 1521 (31.0%) < 0.001
2013 50,799
(50.8%)
48,786
(51.3%)
48,786 (51.3%) 2013 (41.0%)
2014 23,978
(24.0%)
22,601
(23.8%)
22,601 (23.8%) 1377 (28.0%)
Age in years Mean (SD) 34.01 () 34.84 (19.58) 34.84 (19.58) 19.74 (20.53) < 0.001
Age group 0 to 1 (%) 1935 (1.9%) 1693 (1.8%) 1693 (1.8%) 242 (4.9%) < 0.001
2 to 5 7755 (7.8%) 6324 (6.7%) 6324 (6.7%) 1431 (29.1%)
6 to 9 5415 (5.4%) 4860 (5.1%) 4860 (5.1%) 555 (11.3%)
10 to 17 9184 (9.2%) 8405 (8.8%) 8405 (8.8%) 779 (15.9%)
18 to 34 25,917
(25.9%)
25,059
(26.4%)
25,059 (26.4%) 858 (17.5%)
35 to 59 40,261
(40.3%)
39,531
(41.6%)
39,531 (41.6%) 730 (14.9%)
60 plus 9533 (9.5%) 9217 (9.7%) 9217 (9.7%) 316 (6.4%)
Sex Male (%) 49,103
(49.1%)
46,574
(49.0%)
46,574 (49.0%) 2529 (51.5%) 0.001
Female 50,897
(50.9%)
48,515
(51.0%)
48,515 (51.0%) 2382 (48.5%)
Category of insured
persons
Employed (%) 80,312
(80.3%)
78,390
(82.4%)
78,390 (82.4%) 1922 (39.1%) < 0.001
Self-employed 3109 (3.1%) 2581 (2.7%) 2581 (2.7%) 528 (10.8%)
Unemployed 4720 (4.7%) 3770 (4.0%) 3770 (4.0%) 950 (19.3%)
Social security
beneficiary
75 (0.1%) 11 (0.0%) 11 (0.0%) 64 (1.3%)
Student 1453 (1.5%) 1239 (1.3%) 1239 (1.3%) 214 (4.4%)
Retired 7766 (7.8%) 7211 (7.6%) 7211 (7.6%) 555 (11.3%)
Other 2565 (2.6%) 1887 (2.0%) 1887 (2.0%) 678 (13.8%)
Pharmaceutical costs
previous year
Mean (SD) 311.74€
(2486.59€)
255.63€
(1238.33€)
256.14€
(1242.43€)
2077.62€ (12,240.23€) < 0.001
Fig. 1 Incidence per 1000 insured persons for the years 2012 to 2014 for seven different age groups
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year 2013 with 38.89/1000 insured children of the same
age. The lowest incidence was found in persons aged 60
years and older in 2014.
Complications
To estimate the influenza-attributable complication
rates, the incidence of AOM and CAP was assessed for
the influenza and the control group separately (Fig. 2).
Generally, the incidence of AOM and CAP was higher
in the influenza as compared to the control group for
each year and age group. On average, the influenza-at-
tributable complication rate was 3.30% for AOM and
4.28% for CAP with no significant differences across the
years. The highest influenza-attributable complication
rate was found for AOM in children aged 2 to 5 years in
2014. Across the total study period, the complication
rates for AOM attributable to influenza were 14.41,
10.07, 5.78, 4.12, 2.33, 1.99, 2.76, and 3.29% from the
youngest to the oldest age group. The corresponding
values for CAP were 10.04, 7.80, 5.08, 4.02, 2.35, 3.77,
8.01, and 4.28%.
Across all study years and age groups, the concordance
of both complications was observed significantly more
frequent than expected from their respective marginal
probabilities (Chi-squared test). Multiplying the prob-
ability of AOM with the probability of CAP yields 328
cases with both complications in the influenza group
and 27 cases in the control group, which were to be
expected from the marginal probabilities of both compli-
cations. However, 704 cases with both complications
were observed in the influenza and 142 in the control
group. Because of the low cell counts, no tests were per-
formed stratified by years and age groups.
Hospitalization
The dataset contained 458 persons (0.48%) who were
hospitalized for influenza as the principal diagnosis
across all years and age groups. Regarding the disease
severity, the year 2013 does not only show a higher
incidence but also a higher share of persons being
hospitalized for influenza (2012: 0.39%; 2013: 0.58%;
2014: 0.37%). The age-specific risk of hospitalization
was highest for infants (2.24%) and young children (2
to 5 years: 1.15%) and decreased over age to about
0.30% for persons aged 35 to 59 years. Persons aged
60 years and above showed an increased probability of
hospitalization of 0.84% as compared to younger
adults.
The small number of inpatient stays for a principal
diagnosis of influenza (e.g. only six persons aged 10 to
17 years in 2014) counteracts the discovery of significant
trends in the estimates of the length of stay (LOS). The
average LOS due to influenza (principal diagnosis) was
4.47 days. The oldest age group showed the longest LOS
with 7.05 days, followed by infants aged < 1 year with
4.58 days.
Fig. 2 Complication rates for AOM and CAP in the influenza group and the control group for the years 2012 to 2014
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For influenza patients with complications, the risk of
being hospitalized was dependent on the type of compli-
cation. In both groups (influenza and control), only 40
patients diagnosed with an AOM received inpatient
treatment because of AOM, and no significant difference
could be found between the groups (Z-test for propor-
tions, alpha level 0.05). This corresponds to a
hospitalization rate of 0.45% of persons with AOM in
the influenza group and 0.33% of persons with AOM in
the control group. Because of the low number of obser-
vations, no time or age-specific trend was identified
(data shown in the Additional file 1). With 6.85% in the
influenza group and 5.49% in the control group,
hospitalization rates for persons with CAP were much
higher as compared to AOM.
Similar to influenza, trends in the LOS data for pa-
tients with AOM were hardly recognizable because of
the low number of hospitalizations. Overall, the 29 hos-
pitalized patients with AOM in the influenza group
received on average 4.10 days of inpatient care, com-
pared to 3.82 days for the 11 patients in the control
group. As more persons with CAP were hospitalized, an
age-specific U-shaped trend could be seen for the
control (n = 42) and the influenza group (n = 331). Espe-
cially infants with CAP in the influenza group showed a
prolonged LOS of 5.62 days in comparison to the control
group.
Resource use and costs
Outpatient sector
Persons in the influenza group showed on average 4.60
outpatient physician contacts and caused average costs
of €259.75 compared to 3.47 contacts and costs of
€205.80 of the average person in the control group. As
depicted in Fig. 3, there was a slight increase in out-
patient costs with increasing age. Differences between
the influenza and control group were significant at a
0.05-level (two-sided t-tests).
When selecting only influenza patients with complica-
tions and their matched controls, patients with an AOM
diagnosis had 5.20 visits causing an average €297.13 in
the influenza group and 3.37 visits causing €196.19 in
the control group. Costs in the control group were only
higher than for the influenza group in the year 2012 in
the age group of “6 to 9 years”. The difference of €3 was
not significant (p-value: 0.239).
Inpatient sector
The average inpatient costs per influenza hospitalization
measured via the principal diagnosis were €2033 (SD
€2952) with very little variation between the years (2012:
€1948, 2013: €2079, 2014: €1974). In 2012 and 2013,
age-specific costs followed a U-shape with higher costs
in the youngest and oldest age groups and lower costs in
the groups in the middle. This resembles the LOS trend
found in those years. Costs were relatively stable across
the age groups in 2014, which can be explained by a
higher LOS in the middle age groups coinciding with
lower prices for the coded diagnosis-related groups
(DRGs) in those age groups. No trend for the average
costs could be identified over the years.
The average inpatient costs for patients with AOM in
the influenza group were €1632 (SD: €423) and were sig-
nificantly different from the average costs of €2083 (SD:
€532) in the control group (2-sided t-test; p-value
0.020). Again, the small number of AOM overall makes
the interpretation of the stratified analyses difficult (de-
tailed numbers can be found in the Additional file 1). In-
patient costs for CAP do not differ significantly between
the influenza and the control group (€3995 vs. €2789, p-
value 0.089). While the standard deviations were rela-
tively small for AOM, the variation in costs of patients
with a CAP complication in the influenza group were
very high with a standard deviation of €12,002, leading
to the difference of €1206 to be statistically insignificant.
This is mainly explainable by the influenza-related
hospitalization of a pre-term baby with multiple, con-
genital malformations with a LOS of 101 days in the in-
fluenza group in the age group “0 to 1 years” in the year
2013 which caused €157,463.40.
Prescription medication
Of all patients in the influenza group, 57.4% received in-
fluenza-related drugs, compared to 32.4% of in the con-
trol group. This corresponds to 0.65 more medications
on average and €6.23 in the influenza group (€12.54 vs
€6.31). Differences in the number of medications and
costs were significant for all age groups across all years
at a 0.05 alpha level, and there were only minor differ-
ences over time. While the percentage of persons with
medication and the total pharmaceutical costs increased
with age, no clear age-related trend could be identified
for the differences between the influenza and control
groups.
The number of medications for patients with AOM
was significantly higher in the influenza group compared
to the control group (3.39 vs. 1.42; p-value 0.000), which
can also be seen in the cost difference of €15.46 between
the groups. For CAP, the difference in prescriptions was
slightly lower (1.53; p-value: 0.000) compared to AOM,
but the average CAP patient in the influenza group had
higher costs of €17.58 (p-value: 0.000) compared to the
average patient in the control group.
Sick leave and indirect costs
On average 33.44% of patients in the influenza group
were on sick leave for influenza for 6.71 days. In this es-
timate, the denominator includes also non-working
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persons. Looking at the subset of members of the insur-
ance (i.e., the person/s in a family paying the premium)
whose insurance status is “employed”, the percentage of
persons on sick leave for an influenza diagnosis increases
to 54.9% with a mean duration of 6.87 days. For all in-
sured, the number of working days lost increases with
age from 5.63 days for “18 to 34” to 8.25 days for “60
plus”. The indirect costs associated with this sick leave
are €576.54 per case on average. For each age group, the
costs are dependent on the number of working days lost,
the income and the percentage of persons in the labour
force in each age group, resulting in €251.36 for the age
group “10 to 17”, €370.80 for “18 to 34”, €673.84 for “35
to 59” and €569.46 for the age group “60 plus”.
Total direct cost
The total direct costs per average influenza case in our
sample were €82.90, with higher costs in the youngest
and oldest age groups. As can be seen from Fig. 4, the
higher overall costs in those groups were mainly caused
by the higher costs for inpatient care for complications
and for influenza itself. The positive entries in the co-
variance matrix (see Additional file 1) between all cost
categories suggest that higher costs in one sector are
correlated with higher costs in other sectors. For
example, the strongest, positive correlation between
costs for pharmaceuticals and outpatient costs could be
explained by more outpatient visits leading to more pre-
scribed medications.
Assuming that the influenza incidence in this study
population corresponds to the incidence in the total
population of the sickness fund providing the data, this
would result in 2,832,610 cases of influenza in the three-
year period. Based on our calculations, in 2013 nearly
twice as many cases have occurred when compared to
2012 and 2014, respectively (1,443,238 vs. 745,845 and
649,334 cases). Multiplying the age-group specific costs
with the expected number of influenza cases in the gen-
eral German population yields total costs of €78,278,429
per year (ranging from €52,879,376 in 2014 to €120,537,
590 in 2012).
Discussion
Our results confirm well-established differences in the
incidence of seasonal influenza by season and by age
groups. Furthermore, our analyses show that complica-
tion rates for influenza-attributable AOM and CAP are
highly age-dependent. We found no significant differ-
ences of the complication rates between the three
seasons included in this analysis. We were also able to
show that the occurrence of both complications in the
same patient is significantly more frequent than it could
be expected from the marginal probabilities of the com-
plications. The youngest and oldest age groups carried
the highest burden of influenza measured by incidence
and complication rates. Regarding the economic burden,
the presented results suggest no strong cost differences
per case between the years. Analogously to the disease
burden, the youngest and oldest age group cause the
highest mean costs among all age groups. Costs for out-
patient care and pharmaceuticals are relatively similar
for all age groups. Cost differences result from higher
costs of inpatient care for influenza itself and influenza-
related complications, respectively.
Fig. 3 Outpatient costs in Euro (reference year 2014) of patients in the influenza (dark grey) and control (light grey) group by age group and year
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With regard to the incidence estimates, our results
are comparable to the findings of the German Influ-
enza surveillance at the Robert Koch-Institute. The
four reports for the seasons 2011/12, 2012/13, 2013/
14 and 2014/15 [19–22] estimate the number of influ-
enza-related excess consultations per 100,000 inhabi-
tants also to be highest among the youngest age-
group and to be the lowest in the age-group of
people above 60 years of age. Our findings are also in
line with the severity of the different seasons, i.e. the
reports show the highest number of excess consult-
ation in the year 2013 and a fairly equal number in
the years 2012 and 2014.
The results presented on resource use and costs in this
study can only to some extent be compared to previous
studies for Germany. The only two recent studies on in-
fluenza-associated disease burden and costs that were
identified for Germany differed in their scope and the
applied methods [16, 23]. While Ehlken et al. did not
calculate incidence rates, our incidence estimates of
0.93% in 2012 and 1.73% in 2013 are comparable to the
estimate of 1.7% estimated by Haas for the 2012/13
season. The complication rates for AOM and CAP cal-
culated in our study show a similar trend across the age
groups as compared to the figures presented by Haas et
al. but each with a higher level. For example, Haas et al.
estimated the influenza-attributable CAP to be 2.3%
compared to 4.28% in our study. Ehlken et al. reported a
complication rate of 1.6% for CAP in children (5.86% in
our study) and 5.4% in adults (3.82%). The difference be-
tween the studies may be explained by relatively low
numbers of CAP cases in all three studies. For AOM,
Ehlken et al. found higher rates for children (13.4% vs.
7.09% in our study) but lower rates for adults (0.9% vs
2.20%). The complication rates for AOM as found by
Haas et al. correspond well across the age groups, al-
though on a lower level. For instance, for the age
group “0 to 1”, the authors found a difference of
11.0% between influenza and control group compared
to 14.41% in our study. This might be caused by dif-
ferent definition of the complications with regard to
the selected diagnoses in the inpatient and outpatient
sector documented in German routine data. Differ-
ences to Ehlken et al. might also be caused by differ-
ences in season-specific influenza epidemiology, e.g.
the dominant strain circulating or the match of the
seasonal vaccine, as the studies cover different
seasons.
Regarding the cost estimates, the study by Ehlken et
al. estimated the cost of one influenza episode to be
€514 for adults and €105 for children from a societal
perspective and €59 and €66 from a third-party payer
perspective. Unfortunately, Haas et al. did not provide
total cost estimates per influenza case or episode, but
their estimates on the costs for outpatient care exceed
the estimates of Ehlken et al. and our study fourfold
(€224 vs. €34.51 vs. €53.95, respectively). Also, the esti-
mates of Haas et al. for the costs per inpatient influenza
case exceed our estimates (€5832 vs. €2033). For the
outpatient sector, this may be due to the missing control
group in the study by Haas et al. The corresponding
costs of just the influenza group in our study are
€259.75. The difference in outpatient costs might be
explained by outliers.
Fig. 4 Total, average, influenza-attributable costs per influenza case
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Our study has several limitations. Firstly, the time
period covered by the data did not coincide with the
start and the end of the influenza seasons. Hence, the
year 2012 contains the later part of the 2011/12 season
and the first part of the 2012/13 season. By the nature of
claims data, our dataset only contains cases of influenza
seeking medical attendance. Thus, we might underesti-
mate the burden of the disease as symptomatic cases
who do not seek medical attention are not considered
in the analysis. More generally, the estimation of the
burden of disease of influenza is challenging to assess,
since definition and diagnostic procedures differ, in-
formation on seek of medical attendance partly lacks,
and virus circulation and vaccine fit differ almost
every year.
Further, no out-of-pocket payments that are not re-
imbursed by the German sickness funds are part of
our analysis. In this context, it is important to men-
tion that the definition of the influenza group –
including only patients with a J09, J10 or J11
diagnosis – is rather conservative. In this context, the
high percentage of controls with influenza-related
medication might be an indicator although many of
the pharmaceuticals listed in Table 1 are used for
various other medical conditions, e.g. ibuprofen or
other analgesics. Additionally, it is not possible to ex-
clude biases that may arise from the population of
the sickness fund which was used for the analysis in
this study. However, the sickness fund covers nearly
9.98, 10.42 and 10.90% of the general German popu-
lation in the years 2012, 2013 and 2014, respectively.
Finally, we did not include cardiovascular or neuro-
logical complications for which the link to influenza
is not firmly established. To detect those complica-
tions and estimate their economic burden, a larger
dataset would be necessary. Hence, our estimates can
be seen as conservative.
Conclusions
In summary, our study suggests that the economic bur-
den of influenza on a population level corresponds to
the high non-economic burden of disease of influenza
found for Europe [24]. Even if only direct costs are con-
sidered, our estimates of €78,278,429 per year are nearly
as high as the estimates for herpes zoster and postherpe-
tic neuralgia with €105 million [25] and amount to one
third of the yearly spending on prostate cancer of €244
million in Germany [26]. Costs are especially high for
persons being defined as “high risk” from a clinical per-
spective and among children 2 to 5 years old. Further re-
search could focus on the cost-effectiveness of a general,
seasonal vaccination in dependency of the age at admin-
istration of the vaccine.
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